Bio-Techne Corp (TECH) has consistently remained in the limelight due to its strong financial and market performances, as well as collaborations, leadership transitions and litigation updates. Notable events include participation in various healthcare conferences and financial results for Q1, Q2 and Q3 of fiscal 2024 - reporting a mixed performance amid challenging market dynamics. A point worth mentioning is the company's raised price target to $81.00, demonstrating the financial market's growing confidence. It also declared a dividend, signaling a returned fiscal health.
Bio-Techne also announced a new distribution agreement with Thermo Fisher Scientific and a partnership with Nikon to expand access to innovative instruments.
Bio-Techne's robustness in the market is strengthened by various institutions and firms purchasing shares. In particular, First Trust Direct Indexing L.P. bought 388 shares, GAMMA Investing LLC opened a new position, Russell Investments Group Ltd. boosted its stockholding and the Louisiana State Employees Retirement System bought 9600 shares.
Bio-Techne is also engaged in legal battles, with a patent infringement lawsuit filed against Molecular Instruments. Important revelations showed
Bio-Techne's CEO remuneration and analysts' forecast after the company beat and missed EPS by 7.6% and 36%, respectively. Other key updates include the appointment of new leaders, receiving CiteAb's ELISA kit supplier of the year award, and Bio-Techne surpassing 10,000 peer-reviewed publications citing RNAscope technology.
Bio-Techne Corp TECH News Analytics from Wed, 03 Mar 2021 08:00:00 GMT to Wed, 08 May 2024 14:53:00 GMT -
Rating 8
- Innovation 7
- Information 9
- Rumor -2
